Replies to post #99010 on Biotech Values

[genisi]

The Protonix case

The ruling on the invalidity arguments shifts the outcome of the patent litigation against Teva. There is still the patent misuse arguments but I don't think it could win the case. The fact the court hasn't ordered a reset of the date of Teva's regulatory approval to sell its generic and that "Teva is not prohibited from making further sales prior to January 2011", sounds to me that Teva is now actually allowed to sell its generic without a further risk.